NPJ Vaccines最新文献_第7页

A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs. 对豚鼠安全有效的拉沙病毒减毒活疫苗候选产品。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-17 DOI: 10.1038/s41541-024-01012-w

Brian D Carey, Shuiqing Yu, Jillian Geiger, Chengjin Ye, Louis M Huzella, Rebecca J Reeder, Monika Mehta, Shawn Hirsch, Rebecca Bernbaum, Beatrice Cubitt, Bapi Pahar, Scott M Anthony, Anthony Marketon, John G Bernbaum, Julie P Tran, Ian Crozier, Luis Martínez-Sobrido, Gabriella Worwa, Juan Carlos de la Torre, Jens H Kuhn

{"title":"A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.","authors":"Brian D Carey, Shuiqing Yu, Jillian Geiger, Chengjin Ye, Louis M Huzella, Rebecca J Reeder, Monika Mehta, Shawn Hirsch, Rebecca Bernbaum, Beatrice Cubitt, Bapi Pahar, Scott M Anthony, Anthony Marketon, John G Bernbaum, Julie P Tran, Ian Crozier, Luis Martínez-Sobrido, Gabriella Worwa, Juan Carlos de la Torre, Jens H Kuhn","doi":"10.1038/s41541-024-01012-w","DOIUrl":"10.1038/s41541-024-01012-w","url":null,"abstract":"Lassa virus (LASV) is a rodent-borne mammarenavirus that causes tens to hundreds of thousands of human infections annually in Western Africa. Approximately 20% of these infections progress to Lassa fever (LF), an acute disease with case-fatality rates from ≈20-70%. Currently, there are no approved vaccines or specific therapeutics to prevent or treat LF. The LASV genome consists of a small (S) segment that has two genes, GP and NP, and a large (L) segment that has two genes, L and Z. In both segments, the two genes are separated by non-coding intergenic regions (IGRs). Recombinant LASVs (rLASVs), in which the L segment IGR was replaced with the S segment IGR or in which the GP gene was codon-deoptimized, lost fitness in vitro, were highly attenuated in vivo, and, when used as vaccines, protected domesticated guinea pigs from otherwise lethal LASV exposure. Here, we report the generation of rLASV/IGR-CD, which includes both determinants of attenuation and further enhances the safety of the vaccine compared with its predecessors. rLASV/IGR-CD grew to high titers in Vero cells, which are approved for human vaccine production, but did not cause signs of disease or pathology in guinea pigs. Importantly, guinea pigs vaccinated with rLASV/IGR-CD were completely protected from disease and death after a typically lethal exposure to wild-type LASV. Our data support the development of rLASV/IGR-CD as a live-attenuated LF vaccine with stringent safety features.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"220"},"PeriodicalIF":6.9,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach. 基于镶嵌血凝素方法的通用乙型流感灭活疫苗的临床前评估。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-17 DOI: 10.1038/s41541-024-01014-8

Irene González-Domínguez, Eduard Puente-Massaguer, Adam Abdeljawad, Tsoi Ying Lai, Yonghong Liu, Madhumathi Loganathan, Benjamin Francis, Nicholas Lemus, Victoria Dolange, Marta Boza, Stefan Slamanig, Jose Luis Martínez-Guevara, Florian Krammer, Peter Palese, Weina Sun

{"title":"Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach.","authors":"Irene González-Domínguez, Eduard Puente-Massaguer, Adam Abdeljawad, Tsoi Ying Lai, Yonghong Liu, Madhumathi Loganathan, Benjamin Francis, Nicholas Lemus, Victoria Dolange, Marta Boza, Stefan Slamanig, Jose Luis Martínez-Guevara, Florian Krammer, Peter Palese, Weina Sun","doi":"10.1038/s41541-024-01014-8","DOIUrl":"10.1038/s41541-024-01014-8","url":null,"abstract":"We have developed a new universal influenza B vaccination strategy based on inactivated influenza B viruses displaying mosaic hemagglutinins (mHAs). Recombinant mHA viruses were constructed by replacing the four major antigenic sites of influenza B virus HAs, with those from exotic avian influenza A virus HAs. Sequential vaccination of naïve mice with mHA-based vaccines elicited higher immune responses towards the immuno-subdominant conserved epitopes of the HA than vaccination with wildtype viruses. Among the different preparations tested, mHA split vaccines were less immunogenic than their whole inactivated virus counterparts. This lower immunogenicity was overcome by the combination with adjuvants. mHA split vaccines adjuvanted with a Toll-like receptor-9 agonist (CpG 1018) increased Th1 immunity and in vivo cross-protection, whereas adjuvanting with an MF59-like oil-in-water nano-emulsion (AddaVax) enhanced and broadened humoral immune responses and antibody-mediated cross-protection. The mHA vaccines with or without adjuvant were subsequently evaluated in mice that were previously immunized to closely mimic human pre-existing immunity to influenza B viruses and the contribution of innate and cellular immunity was evaluated in this model. We believe these preclinical studies using the mHA strategy represent a major step toward the evaluation of a universal influenza B virus vaccine in clinical trials.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"222"},"PeriodicalIF":6.9,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses. B/山形系人类流感病毒明显灭绝的影响。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-16 DOI: 10.1038/s41541-024-01010-y

Ian G Barr, Kanta Subbarao

引用次数: 0

Mapping global public perspectives on mRNA vaccines and therapeutics. 了解全球公众对 mRNA 疫苗和疗法的看法。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-14 DOI: 10.1038/s41541-024-01019-3

Jiaxiang Xu, Zhengdong Wu, Lily Wass, Heidi J Larson, Leesa Lin

引用次数: 0

A highly immunogenic UVC inactivated Sabin based polio vaccine. 基于 Sabin 的高免疫原性紫外线灭活脊髓灰质炎疫苗。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-14 DOI: 10.1038/s41541-024-00995-w

Gregory J Tobin, John K Tobin, Taralyn J Wiggins, Ruth V Bushnell, Arina V Kozar, Matthew F Maale, David A MacLeod, Heather N Meeks, Michael J Daly, Stephen J Dollery

{"title":"A highly immunogenic UVC inactivated Sabin based polio vaccine.","authors":"Gregory J Tobin, John K Tobin, Taralyn J Wiggins, Ruth V Bushnell, Arina V Kozar, Matthew F Maale, David A MacLeod, Heather N Meeks, Michael J Daly, Stephen J Dollery","doi":"10.1038/s41541-024-00995-w","DOIUrl":"10.1038/s41541-024-00995-w","url":null,"abstract":"Despite their efficacy, the currently available polio vaccines, oral polio vaccine (OPV) and inactivated polio vaccine (IPV), possess inherent flaws posing significant challenges in the global eradication of polio. OPV, which uses live Sabin attenuated strains, carries the risk of reversion to pathogenic forms and causing vaccine-associated paralytic poliomyelitis (VAPP) and vaccine-derived polio disease (VDPD) in incompletely vaccinated or immune-compromised individuals. Conventional IPVs, which are non-replicative, are more expensive to manufacture and introduce biohazard and biosecurity risks due to the use of neuropathogenic strains in production. These types of limitations have led to a call by the Global Polio Eradication Initiative and others for the development of updated polio vaccines. We are developing a novel Ultraviolet-C radiation (UVC) inactivation method that preserves immunogenicity and is compatible with attenuated strains of polio. The method incorporates an antioxidant complex, manganese-decapeptide-phosphate (MDP), derived from the radioresistant bacterium Deinococcus radiodurans. The inclusion of MDP protects the immunogenic neutralizing epitopes from damage during UVC inactivation. The novel vaccine candidate, ultraIPVTM, produced using these methods demonstrates three crucial attributes: complete inactivation, which precludes the risk of vaccine-associated disease; use of non-pathogenic strains to reduce production risks; and significantly enhanced yield of doses per milligram of input virus, which could increase vaccine supply while reducing costs. Additionally, ultraIPVTM retains antigenicity post-freeze-thaw cycles, a testament to its robustness.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"217"},"PeriodicalIF":6.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis. 一种多表位亚单位疫苗，可针对猪链球菌的不同血清型提供广泛的交叉保护。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-14 DOI: 10.1038/s41541-024-01015-7

Jianan Liu, Zhen Zhang, Wanxia Pu, Xinming Pan, Pei Li, Qiankun Bai, Song Liang, Caiying Li, Yong Yu, Huochun Yao, Jiale Ma

{"title":"A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis.","authors":"Jianan Liu, Zhen Zhang, Wanxia Pu, Xinming Pan, Pei Li, Qiankun Bai, Song Liang, Caiying Li, Yong Yu, Huochun Yao, Jiale Ma","doi":"10.1038/s41541-024-01015-7","DOIUrl":"10.1038/s41541-024-01015-7","url":null,"abstract":"Streptococcus suis infection represents a major challenge in pig farming and public health due to its zoonotic potential and diverse serotypes, while existing vaccines lack effective cross-protection. This study employed reverse vaccinology and immunoinformatics to identify 8 conserved proteins across 11 prevalent serotypes of S. suis. 16 candidate epitopes were selected to design three multi-epitope antigens against S. suis (designated as MEASs), which fused with a dendritic cell-targeting peptide to improve antigen presentation in host. Purified MEASs displayed favorable cross-reactogenicity against 29 serotype-specific antiserums. Robust humoral and cellular immune responses can be induced by MEAS 1 and MEAS 3 in a mouse model, which provided substantial protection against virulent strains from two different serotypes. In particular, their immune serums exhibited positive opsonization effects within bloodstream and macrophage phagocytosis. Taken together, we identified two promising MEASs with excellent cross-protection, offering potential in preventing S. suis infections in a mouse model.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"216"},"PeriodicalIF":6.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models. 利用时间到事件模型中的免疫相关数据提高疫苗疗效评估的精确度。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-11 DOI: 10.1038/s41541-024-00937-6

Julie Dudášová, Zdeněk Valenta, Jeffrey R Sachs

引用次数: 0

Irradiated whole cell Chlamydia vaccine confers significant protection in a murine genital tract challenge model. 在小鼠生殖道挑战模型中，辐照全细胞衣原体疫苗可提供显著的保护。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-11 DOI: 10.1038/s41541-024-00968-z

Kieran C Broder, Vera Y Matrosova, Rok Tkavc, Elena K Gaidamakova, Lam Thuy Vi Tran Ho, Andrew N Macintyre, Anthony Soc, Aissata Diallo, Stephen C Darnell, Sarah Bash, Michael J Daly, Ann E Jerse, George W Liechti

{"title":"Irradiated whole cell Chlamydia vaccine confers significant protection in a murine genital tract challenge model.","authors":"Kieran C Broder, Vera Y Matrosova, Rok Tkavc, Elena K Gaidamakova, Lam Thuy Vi Tran Ho, Andrew N Macintyre, Anthony Soc, Aissata Diallo, Stephen C Darnell, Sarah Bash, Michael J Daly, Ann E Jerse, George W Liechti","doi":"10.1038/s41541-024-00968-z","DOIUrl":"10.1038/s41541-024-00968-z","url":null,"abstract":"Chlamydia trachomatis infections are the most common bacterial STIs globally and can lead to serious morbidity if untreated. Development of a killed, whole-cell vaccine has been stymied by coincident epitope destruction during inactivation. Here, we present a prototype Chlamydia vaccine composed of elementary bodies (EBs) from the related mouse pathogen, Chlamydia muridarum (Cm). EBs inactivated by gamma rays (Ir-Cm) in the presence of the antioxidant Mn2+-Decapeptide (DEHGTAVMLK) Phosphate (MDP) are protected from epitope damage but not DNA damage. Cm EBs gamma-inactivated with MDP retain their structure and provide significant protection in a murine genital tract infection model. Mice vaccinated with Ir-Cm (+MDP) exhibited elevated levels of Cm-specific IgG and IgA antibodies, reduced bacterial burdens, accelerated clearance, and distinctive cytokine responses compared to unvaccinated controls and animals vaccinated with EBs irradiated without MDP. Preserving EB epitopes with MDP during gamma inactivation offers the potential for a polyvalent, whole-cell vaccine against C. trachomatis.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"207"},"PeriodicalIF":6.9,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera. 人和小鼠血清中和 SARS-CoV-2 KP.1、KP.1.1、KP.2 和 KP.3。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-11 DOI: 10.1038/s41541-024-01016-6

Kun Xu, Yaling An, Xueyuan Liu, Haitang Xie, Dedong Li, Ting Yang, Minrun Duan, Yuanzhuo Wang, Xin Zhao, Lianpai Dai, George F Gao

引用次数: 0

Assessing acute kidney injury risk after COVID vaccination and infection in a large cohort study. 在一项大型队列研究中评估 COVID 疫苗接种和感染后的急性肾损伤风险。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-08 DOI: 10.1038/s41541-024-00964-3

Yuanyi Pan, Yun Han, Chuan Zhou, Jie Zheng, Lili Zhao, Xianwei Ye, Yongqun He

引用次数: 0